| Primary |
| Chronic Obstructive Pulmonary Disease |
60.0% |
| Hypertension |
20.0% |
| Thrombosis Prophylaxis |
20.0% |
|
| Bleeding Varicose Vein |
100.0% |
|
| Secondary |
| Surgery |
51.7% |
| Stent Placement |
17.2% |
| Hypertension |
13.8% |
| Hypercholesterolaemia |
6.9% |
| Acute Myocardial Infarction |
4.3% |
| Type 2 Diabetes Mellitus |
4.3% |
| Product Used For Unknown Indication |
1.7% |
|
| Wheezing |
53.3% |
| Headache |
13.3% |
| Discomfort |
6.7% |
| Fluid Retention |
6.7% |
| Mydriasis |
6.7% |
| Oedema |
6.7% |
| Weight Increased |
6.7% |
|
| Concomitant |
| Hypertension |
13.2% |
| Drug Use For Unknown Indication |
12.6% |
| Acute Myocardial Infarction |
12.4% |
| Dyspnoea |
11.4% |
| Pain |
6.1% |
| Prophylaxis |
5.1% |
| Product Used For Unknown Indication |
4.6% |
| Type 2 Diabetes Mellitus |
4.0% |
| Diabetes Mellitus |
3.0% |
| Cardiac Failure |
2.8% |
| Chest Pain |
2.6% |
| Haemoptysis |
2.6% |
| Ischaemic Heart Disease Prophylaxis |
2.6% |
| Nausea |
2.6% |
| Renal Cell Carcinoma Stage Unspecified |
2.6% |
| Asthma |
2.3% |
| Atrial Fibrillation |
2.3% |
| Constipation |
2.3% |
| Osteoporosis |
2.3% |
| Arthralgia |
2.2% |
|
| Pneumothorax |
11.3% |
| Nephrogenic Systemic Fibrosis |
10.0% |
| Weight Increased |
10.0% |
| Fluid Retention |
8.8% |
| Glioblastoma |
6.3% |
| Haemoptysis |
5.0% |
| Urinary Tract Infection |
5.0% |
| Atypical Femur Fracture |
3.8% |
| Metastases To Central Nervous System |
3.8% |
| Osteoarthritis |
3.8% |
| Pleural Effusion |
3.8% |
| Post Procedural Fistula |
3.8% |
| Psoriasis |
3.8% |
| Renal Impairment |
3.8% |
| Skin Hypertrophy |
3.8% |
| Subdural Haematoma |
3.8% |
| Hyponatraemia |
2.5% |
| Intermittent Claudication |
2.5% |
| International Normalised Ratio Increased |
2.5% |
| Pneumonitis |
2.5% |
|
